Scinai Immunotherapeutics Ltd.

Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer programs April 24, 2026 -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), today announced that it has entered into a securities purchase agreement with an institutional life sciences investor, as well as with new and existing institutional and accredited investors, for the purchase and sale of 5,208,333 American Depositary Shares (ADSs), each representing 4,000 ordinary shares, at a purchase price of $0.48 per ADS, as well as a Series A warrant to purchase up to 5,208,333 ADSs at an exercise price of $0.48 per ADS, exercisable immediately with a term of two years, and a Series B warrant to purchase up to 5,208,333 ADSs at an exercise price of $0.55 per ADS, exercisable immediately with a term of five years. In addition, the Company entered into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of warrants to purchase up to 229,310 ADSs of its ordinary shares (the "Existing Warrants") at an exercise price of $0.48 per ADS. In consideration for the immediate exercise in full of the Existing Warrants for cash, the investor will receive in a private placement new unregistered warrants to purchase up to 458,621 ADSs (the "New Warrants"). The New Warrants will have an exercise price of $0.55 per ADS, will be exercisable immediately, and will expire five (5) years from the date of issuance. The aggregate gross proceeds from the private placement and the warrant inducement transaction are approximately $2.61 million, before deducting fees and expenses, and the closing of the transactions is expected to occur on or about April 27, 2026, subject to satisfaction of customary closing conditions. Scinai intends to use the net proceeds, together with existing cash resources, to support the expansion of its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. The Company believes this financing will support the execution of its growth strategy. A.G.P./Alliance Global Partners acted as the sole financial advisor for the transactions. The offer and sale of the foregoing securities will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder. Accordingly, the securities issued in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in this warrant inducement transaction, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies. The content above comes from the network. if any infringement, please contact us to modify.

👋 各位读者朋友，早上好！今天是 2026年4月16日（星期四），为您带来今日医药晨间快报。【本期核心动向】· MNC并购内幕曝光：SEC文件揭秘默沙东67亿美元收购Terns砍价10亿美元全过程· CRO整合加速：佰君生物与滬港中科签署战略整合协议，构建临床前全链条；Scinai完成对Recipharm以色列工厂收购· BD出海持续爆发：海思科Q1净利预增超9倍；甘李药业GLP-1半年完成三笔海外授权· 新药审批密集：全球首款mRNA肉毒、全球首个iPSC癫痫细胞药物实现中美双批📰 MNC·全球并购与药企动态1. 【默沙东67亿美元】SEC文件曝光收购Terns砍价10亿美元内幕一份递交至SEC的文件披露，默沙东对Terns的收购历经多轮博弈。初始报价为每股61美元，后因竞购方退出，默沙东将报价大幅下调至每股50美元，最终以每股53美元成交，总价约67亿美元，相当于砍价近10亿美元。2. 【太阳制药】拟120亿美元竞购欧加隆，印度药企最大海外并购印度太阳制药已完成对欧加隆的尽职调查，正筹备120亿美元约束性报价。欧加隆2025年成熟品牌药收入36.9亿美元，若交易达成将创印度药企海外并购纪录。3. 【百时美施贵宝】84亿美元锁定中国百利天恒双抗ADCBMS以首付款13亿美元获得百利天恒EGFR×HER3双抗ADC全球权益，总金额最高84亿美元，创全球ADC单药授权总价纪录。头部产品Enhertu 2025年全球销售额约49.83亿美元。4. 【吉利德】50亿美元收购Tubulis，夯实ADC管线吉利德以50亿美元收购德国Tubulis（首付款31.5亿美元+最高18.5亿美元里程碑），获得靶向NaPi2b的TUB-040等ADC管线。此前曾以210亿美元收购Immunomedics拿下Trodelvy，足见对ADC赛道的志在必得。🔬 CRO/CDMO·行业整合加速5. 【佰君生物×滬港中科】签署战略整合协议，构建全链条服务4月13日，佰君生物与滬港中科在佰君生物上海总部举行战略整合签约仪式。双方将深度整合资源，构建覆盖药物发现、临床前研究到IND申报的全链条服务体系。佰君生物约85%收入来自海外市场，滬港中科国内客户占比超90%，客户结构形成高度互补。6. 【Scinai】完成对Recipharm以色列工厂收购，强化CDMO平台Scinai完成对Recipharm以色列Yavne工厂100%股权的收购，同时与Recipharm签订长期商业合作协议，可提供重组蛋白、小分子、多肽、抗体、寡核苷酸等全品类CDMO服务，覆盖从早期开发到商业化全流程。7. 【CMIC集团】完成日本CRO/CDMO业务重组日本CMIC集团宣布完成旗下多家CRO/CDMO公司的内部重组整合，优化药物研发服务体系，强化在日本本土和亚太地区的市场竞争力，涵盖临床试验外包、药品生产制造、现场支持和市场解决方案等全链条业务。💼 中国创新药BD·出海持续爆发8. 【海思科】Nav1.8抑制剂授权艾伯维，Q1净利预增超9倍海思科将两款Nav1.8抑制剂大中华区外全球权益授权艾伯维，获3000万美元预付款+7.15亿美元里程碑款。受益于此，Q1归母净利润预计4.77亿-5.57亿元，同比增长923%-1095%，单季利润已超去年全年。9. 【甘李药业】GLP-1双周制剂授权韩国，半年完成三笔海外授权甘李药业与韩国JW Pharma签署独家许可协议，授权GLP-1双周制剂博凡格鲁肽注射液在韩国开发和商业化，潜在总金额达8110万美元。这是该产品半年内第三笔海外授权，此前已授权拉丁美洲和印度市场。10. 【云顶新耀】2.5亿美元收购海森新加坡，搭建亚太商业化平台云顶新耀以2.5亿美元收购海森新加坡100%股权，获亚太地区14款慢性病成熟品牌产品及完整商业化团队，2025财年收入约5.66亿元、EBITDA约1.88亿元，交割后将立即增厚公司业绩。11. 【科创板成绩单】28家创新药企2025年整体扭亏，合计营收约740亿元科创板28家披露业绩快报的创新药公司2025年合计营收约740亿元，同比增长近30%，整体归母净利润约16亿元，成功扭转亏损局面。BD交易首付款总额超51亿美元，里程碑总额突破400亿美元。💊 新药审批·技术前沿突破12. 【全球首款mRNA肉毒】星核迪赛DSL201实现中美临床双批苏州星核迪赛DSL201注射液获CDE临床默示许可，叠加此前FDA批准，成为全球首款进入临床阶段的mRNA编码A型肉毒毒素创新药，标志着mRNA技术从疫苗领域走向医美治疗赛道，颠覆了传统肉毒毒素沿用近百年的技术体系。13. 【全球首个iPSC癫痫药物】跃赛生物UX-GIP001实现中美IND双批上海跃赛生物自主研发的全球首个难治性癫痫iPSC来源异体细胞药物UX-GIP001，接连获得FDA与CDE临床试验批准，成为目前全球唯一一款在iPSC细胞治疗癫痫领域实现中美双批的创新产品。14. 【正大天晴】泛KRAS抑制剂TQB3205获FDA批准临床正大天晴自主研发的1类创新口服泛KRAS抑制剂TQB3205获得FDA批准，开展针对晚期恶性肿瘤的临床试验。泛KRAS抑制剂可同时靶向多种KRAS突变蛋白，突破单一靶点药物覆盖范围受限的瓶颈。15. 【百济神州】塔拉妥单抗获NMPA附条件批准，治疗小细胞肺癌百济神州与安进共同开发的靶向DLL3和CD3的双特异性TCE抗体塔拉妥单抗，经优先审评程序获得NMPA附条件批准，用于既往接受过至少2种系统性治疗失败的广泛期小细胞肺癌成人患者。📊 资本市场·资金动态16. 【医药板块】昨日主力资金净流入40.83亿元，居全行业首位4月15日，A股医药生物行业全天主力资金净流入40.83亿元，居31个申万一级行业首位。化学制药板块净流入9.07亿元，创新药概念板块获净流入37.50亿元，康恩贝净流入2.58亿元居首。📖 晨间共勉“从mRNA肉毒到iPSC癫痫药，中国创新正以前沿技术定义下一个十年。”—— 佚名【免责声明】 本快报基于公开信息整理，旨在传递行业动态，不构成任何投资或医疗建议。关注我，每日清晨，与您共读医药新的一天。

Plus, news about WuXi XDC: 💰 Shionogi’s BARDA contract for Fetroja: The drugmaker has been awarded a contract worth $119 million, with the potential to increase to $482 million, from the Biomedical Advanced Research and Development Authority. Shionogi will establish a US factory to make the antibiotic Fetroja, which is used to treat gram-negative bacteria infections. The contract will also fund a supplemental new drug application for Fetroja as a treatment for hospital-acquired and ventilator-associated bacterial pneumonia in children. 🏭 Scinai Immunotherapeutics completes setup of CDMO business: After its reorg , the company has cemented the setup of its new CDMO arm, called Scinai Biopharma Services. All CDMO services and roles have been moved to a facility in Yavne, Israel, which Scinai acquired from Recipharm earlier this year. Scinai expects its CDMO unit to generate $5 million in revenue for 2026, after collecting $1.3 million in 2025. 🤝 Akari Therapeutics and WuXi XDC team up: Akari has partnered with WuXi Biologics’ ADC spin-off WuXi XDC to develop and manufacture Akari’s PH1 payload. The PH1 payload is being used in Akari’s lead Phase 1 asset called AKTX-101 for metastatic urothelial cancer. The payload is designed to disrupt RNA splicing in cancer cells.